Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Monitor Liechtenstein.
Press releases published on May 15, 2025
FuturHealth Under Review: Best GLP-1 Semaglutide Medication Prescription for Weight Loss with No Insurance
GlobeNewswire
·
May 15, 2025
San Diego, May 15, 2025 (GLOBE NEWSWIRE) -- In This Article, You’ll Discover: Why millions of Americans are turning to GLP-1 semaglutide prescriptions for weight loss without insurance The top pain points consumers face in traditional weight loss and …
HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results
GlobeNewswire
·
May 15, 2025
MIRAMAR, Fla., May 15, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by …
Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy
GlobeNewswire
·
May 15, 2025
TEL AVIV, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals (NYSE and TASE: TEVA) today announced that Moody's Investor Services (“Moody's”) has raised the company's corporate credit rating to Ba1, outlook stable; from Ba2, outlook positive. …
BioSyent Releases Financial Results for First Quarter 2025
GlobeNewswire
·
May 15, 2025
MISSISSAUGA, Ontario, May 15, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the first quarter (Q1) ended March 31, 2025. Key highlights include: (CAD) Q1 2025 % Change vs. Q1 2024 Trailing …
BioSyent Declares Second Quarter 2025 Dividend
GlobeNewswire
·
May 15, 2025
MISSISSAUGA, Ontario, May 15, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.05 per common share, payable in Canadian Dollars on …
Rakovina Therapeutics Announces Strategic Private Placement, Convertible Debt Financing, and Share Consolidation to Accelerate US-Focused Growth and AI-Powered Oncology Innovation
GlobeNewswire
·
May 15, 2025
VANCOUVER, British Columbia, May 15, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered …
60 Degrees Pharmaceuticals Announces First Quarter 2025 Results
GlobeNewswire
·
May 15, 2025
Q1 2024 net product revenues increased 55% year-over-year to $163.6 thousand. Gross profit increased 124% to $90.3 thousand. WASHINGTON, May 15, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a …
Assemblée Générale Mixte du 11 juin 2025
GlobeNewswire
·
May 15, 2025
Châtillon, France, le 15 mai 2025 Assemblée Générale Mixte du 11 juin 2025 Modalités de mise à disposition des informations et documents préparatoires à l’Assemblée Générale Mixte DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market …
Precision Optics Reports Third Quarter Fiscal Year 2025 Financial Results
GlobeNewswire
·
May 15, 2025
GARDNER, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, announced operating results on an …
Globus Medical Announces $500 Million Share Repurchase Program
GlobeNewswire
·
May 15, 2025
AUDUBON, Pa., May 15, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced that its Board of Directors has authorized a share repurchase program of up to $500 million of the Company’s …
SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 15, 2025
Ibrexafungerp clinical hold lifted by the FDA. SCYNEXIS working to resolve a disagreement with GSK involving the restart of the MARIO study. GSK remains committed to the commercialization of Brexafemme. Hansoh recently received Chinese (NMPA) approval for …
Vivos Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update
GlobeNewswire
·
May 15, 2025
Year-over-year product revenue increased 8%, and year-over-year operating expenses decreased 5% as Vivos sets the stage for its Sleep Center of Nevada acquisition and continued advancement of its new marketing and distribution model Management to Host …
Milestone Scientific Reports Revenue of $2.2 Million and Provides Business Update for the First Quarter of 2025
GlobeNewswire
·
May 15, 2025
ROSELAND, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update and reported financial …
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025
GlobeNewswire
·
May 15, 2025
BASEL, Switzerland and LONDON and NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 29, 2025, to report its financial results for the …
Range Impact Reports 1Q 2025 Financial Results
GlobeNewswire
·
May 15, 2025
Cleveland, Ohio, May 15, 2025 (GLOBE NEWSWIRE) -- Range Impact, Inc. (OTCQB: RNGE) (“Range Impact” or the “Company”), a public impact investing company dedicated to acquiring, reclaiming and repurposing mine sites in Appalachia, reports its results for the …
Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates
GlobeNewswire
·
May 15, 2025
- Duchenne (SGT-003): Participant dosing ongoing in the Phase 1/2 INSPIRE DUCHENNE trial; Solid on track to discuss accelerated pathways with U.S. FDA later in 2025 - - FA (SGT-212): Dosing of first participant anticipated in the second half of 2025 - - …
Senseonics Announces Commencement of $50 Million Public Offering of Common Stock and Concurrent Private Placement
GlobeNewswire
·
May 15, 2025
GERMANTOWN, Md., May 15, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people …
vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update
GlobeNewswire
·
May 15, 2025
Ongoing screening in CATT1 Phase 3 trial evaluating cadisegliatin in patients with type 1 diabetes (T1D) Topline Phase 3 data for cadisegliatin expected in 2H 2026 HIGH POINT, N.C., May 15, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a …
Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update
GlobeNewswire
·
May 15, 2025
LYTENAVA™ (bevacizumab gamma) on track for planned first commercial launches in Germany and the United Kingdom (UK) in Q2 CY2025 Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 in the United States ISELIN, N.J., May 15, 2025 (GLOBE …
Trinity Biotech Publishes Fourth Quarter and Fiscal Year 2024 Financial Results & Provides a Business Update
GlobeNewswire
·
May 15, 2025
DUBLIN, May 15, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, today announced results for the quarter …